Drug interactions between warfarin and lenvatinib in a patient with the CYP2C9*1/*3 and VKORC1-1639G/A genotype

被引：5
作者：
Yagishita, Hironobu [1 ]
Minami, Shinichiro [2 ]
Akamine, Yumiko [1 ]
Kato, Shotaro [1 ]
Iijima, Katsunori [2 ]
Miura, Masatomo [1 ]
机构：
[1] Akita Univ Hosp, Dept Pharm, 1-1-1 Hondo, Akita 0108543, Japan
[2] Akita Univ, Dept Gastroenterol, Grad Sch Med, Akita, Japan
来源：
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | 2019年 / 44卷 / 06期
基金：
日本学术振兴会;
关键词：
interaction; lenvatinib; vitamin K epoxide reductase complex subunit 1; warfarin; CYP2C9; POLYMORPHISMS; DOSE REQUIREMENTS; VKORC1; METABOLISM; ASSOCIATION;
D O I：
10.1111/jcpt.13030
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
What is known and objective Lenvatinib inhibits CYP2C8. (S)-Warfarin is metabolized to (S)-7-hydroxywarfarin by CYP2C9 and (S)-4'-hydroxywarfarin by CYP2C8. Here, we report drug interactions between warfarin and lenvatinib in a patient with CYP2C9*1/*3. Case summary The patient was administered warfarin. His international normalized ratio (INR) was 1.92 before lenvatinib administration. On day 8 after beginning 12 mg/day lenvatinib, plasma trough concentrations of lenvatinib and (S)-warfarin were 33.3 ng/mL and 0.67 mu g/mL, respectively. On day 10, his INR increased to 3.48. What is new and conclusion Lenvatinib-dependent (S)-warfarin inhibition could involve CYP2C9 and CYP2C8. After initiating warfarin plus lenvatinib, INR assays are necessary.
引用
收藏
页码：977 / 980
页数：4
相关论文
共 26 条
[1]   Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation [J].
Anderson, Jeffrey L. ;
Horne, Benjamin D. ;
Stevens, Scott M. ;
Grove, Amanda S. ;
Barton, Stephanie ;
Nicholas, Zachery P. ;
Kahn, Samera F. S. ;
May, Heidi T. ;
Samuelson, Kent M. ;
Muhlestein, Joseph B. ;
Carlquist, John F. .
CIRCULATION, 2007, 116 (22) :2563-2570
[2]   STEREOCHEMICAL ASPECTS OF WARFARIN DRUG-INTERACTIONS - USE OF A COMBINED PHARMACOKINETIC-PHARMACODYNAMIC MODEL [J].
CHAN, E ;
MCLACHLAN, A ;
OREILLY, R ;
ROWLAND, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (03) :286-294
[3]   Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy [J].
Ferder, N. S. ;
Eby, C. S. ;
Deych, E. ;
Harris, J. K. ;
Ridker, P. M. ;
Milligan, P. E. ;
Goldhaber, S. Z. ;
King, C. R. ;
Giri, T. ;
McLeod, H. L. ;
Glynn, R. J. ;
Gage, B. F. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (01) :95-100
[4]  
Food and Drug Administration, 2014, CTR DRUG EV RES LEV
[5]   Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy [J].
Higashi, MK ;
Veenstra, DL ;
Kondo, LML ;
Wittkowsky, AK ;
Srinouanprachanh, SL ;
Farin, FM ;
Rettie, AE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1690-1698
[6]   Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma [J].
Ikeda, Masafumi ;
Okusaka, Takuji ;
Mitsunaga, Shuichi ;
Ueno, Hideki ;
Tamai, Toshiyuki ;
Suzuki, Takuya ;
Hayato, Seiichi ;
Kadowaki, Tadashi ;
Okita, Kiwamu ;
Kumada, Hiromitsu .
CLINICAL CANCER RESEARCH, 2016, 22 (06) :1385-1394
[7]   Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade [J].
Johnson, Philip J. ;
Berhane, Sarah ;
Kagebayashi, Chiaki ;
Satomura, Shinji ;
Teng, Mabel ;
Reeves, Helen L. ;
O'Beirne, James ;
Fox, Richard ;
Skowronska, Anna ;
Palmer, Daniel ;
Yeo, Winnie ;
Mo, Frankie ;
Lai, Paul ;
Inarrairaegui, Mercedes ;
Chan, Stephen L. ;
Sangro, Bruno ;
Miksad, Rebecca ;
Tada, Toshifumi ;
Kumada, Takashi ;
Toyoda, Hidenori .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) :550-U45
[8]   Human P450 metabolism of warfarin [J].
Kaminsky, LS ;
Zhang, ZY .
PHARMACOLOGY & THERAPEUTICS, 1997, 73 (01) :67-74
[9]  
KAMINSKY LS, 1984, DRUG METAB DISPOS, V12, P470
[10]   Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism [J].
King, BP ;
Khan, TI ;
Aithal, GP ;
Kamali, F ;
Daly, AK .
PHARMACOGENETICS, 2004, 14 (12) :813-822
123